Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) EBT (2016 - 2025)

Ultragenyx Pharmaceutical has reported EBT over the past 10 years, most recently at -$127.7 million for Q4 2025.

  • Quarterly EBT rose 3.86% to -$127.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$571.0 million through Dec 2025, down 0.71% year-over-year, with the annual reading at -$571.0 million for FY2025, 0.71% down from the prior year.
  • EBT was -$127.7 million for Q4 2025 at Ultragenyx Pharmaceutical, up from -$179.5 million in the prior quarter.
  • Over five years, EBT peaked at $481.6 million in Q4 2023 and troughed at -$238.8 million in Q3 2022.
  • The 5-year median for EBT is -$142.8 million (2021), against an average of -$91.9 million.
  • The largest YoY upside for EBT was 1287.53% in 2021 against a maximum downside of 574.02% in 2021.
  • A 5-year view of EBT shows it stood at $332.9 million in 2021, then crashed by 146.05% to -$153.3 million in 2022, then skyrocketed by 414.17% to $481.6 million in 2023, then plummeted by 127.58% to -$132.8 million in 2024, then grew by 3.86% to -$127.7 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's EBT are -$127.7 million (Q4 2025), -$179.5 million (Q3 2025), and -$114.0 million (Q2 2025).